Effect of recombinant human brain natriuretic peptide in the treatment of acute heart failure and on tumor necro-sis factor-like weak inducer of apoptosis in patients with acute heart failure
LIU Yun
ZHANG Yuan
HONG Chang-jiang
QIU Jian
Abstract：Objective To assess the alteration of soluble human tumor necrosis factor-like weak inducer of ap-optosis ( TWEAK) in patients with acute heart failure ( AHF) .To investigate the safety and efficacy of recombinant hu-man brain natriuretic peptide ( rhBNP) in the treatment of AHF and its effect on TWEAK.Methods A total of 66 pa-tients with AHF and 22 healthy subjects were enrolled in the AHF group and the control group, respectively.Level of TWEAK was compared between groups.The AHF group was further divided into 2 sub-groups ( Group1, 2 ) .Both Group 1 and Group 2 received standard treatment of heart failure and underlying diseases, and 3-day rhBNP was further applied in Group 1.Results Before treatment, the TWEAK level in AHF group was significantly higher than control group, and there was no difference between Group 1 and Group 2.After treatment for 3 days, the TWEAK level in Group 1 was significantly lower than in Group 2.Statistically significant differences were demonstrated in the improvement of clin-ical symptoms, brain natriuretic peptide ( BNP) level and central venous pressure ( CVP) between the 2 subgroups.Ser-um creatinine level improved in both subgroups with no statistically significant difference between subgroups.Left ventricu-lar end-diastolic diameter ( LVDD) and ejection fraction ( EF) were not statistically significantly different between Group 1 and 2.Conclusion TWEAK may contribute to the development of AHF.Administration of rhBNP can improve the clinical symptoms and laboratory outcomes of AHF patients, and promote elimination of TWEAK without causing malignant arrhythmia and kidney function decline.
Keywords：recombinant human brain natriuretic peptideacute heart failuretumor necrosis factor-like weak
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 2154-2157 )